According to the DRHP, the proposed IPO of the Goa-based company is a combination of a new stock sale of RS 200 Crore and an offer for sale (OFS) of a maximum of 1.25 crore shares.
As part of the OFS, the sales shareholders Exxora Trading LLP, Dr. Chandrasekhar Bhaskaran Nair, Abdul Qadir Mohamed Theruvath and some others.
The company proposes to use the net proceeds of the new issue for the financing of Capex for setting up infrastructure for an R&D facility, a center of excellence, connected office space and for the purchase of factory, machines and other equipment for its Goa and Visakhapatnam units.
The ‘Troeenat’ platform, patented in more than 100 countries, is a new POC Polymerase Chain Reaction (PCR) platform that can operate in resource-restricted settings, because it is edited on batteries, making decentralized diagnosis within an hour.
Molbio Diagnostics, founded in 2000, has five production facilities in India, two of which are in Goa, one in Visakhapatnam (Andhra Pradesh), and two in Bengaluru (Peenya and Machohalli). Facility in Machohalli (Bengaluru), managed by its subsidiary Prognosys Medical Systems, is devoted to the production of radiology products such as ultraportable Röntgensystems, mobile digital röntgensystems, rampond and C-Systemen touched on the floor and C-Systems. ‘Troenat’ test kits per year. In FY25, Molbio Diagnostics, income from the activities of RS 1,020 Crore registered, with a growth of 21.98% compared to FY24. The FY25 win after tax was RS 138.5 Crore.
Srram Natarajan, Chandrasekharan Bhaskaran Nair, Sangeetha Srram, Shiva Srram, Sowmya Srram and Exxora Trading LLP are the promoters of the company.
Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Investment Advisors Limited are the book runners of the issue.
(Disclaimer: recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)
#Diagnostics #company #Molbio #Files #DRHP #SEBI #IPO